Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

6.580 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 6.580
Bid (Size) 6.560 (80)
Ask (Size) 6.590 (30)
Prev. Close 6.580
Today's Range 6.580 - 6.580
52wk Range 2.300 - 17.59
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
-29.32%
-29.32%
1 Month
-0.30%
-0.30%
3 Month
+140.15%
+140.15%
6 Month
+5.11%
+5.11%
1 Year
-57.36%
-57.36%

More News

Read More
Gold Gains Over 1%; Starbucks Shares Move Higher
Via Benzinga
Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?
Via InvestorPlace
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Via Benzinga
Crude Oil Surges 2%; B. Riley Financial Shares Plunge
Via Benzinga
Exposures Fossil Fuels
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
From Brodsky & Smith LLC
Via GlobeNewswire
KE Holdings, KeyCorp, Revance Therapeutics, Starbucks And Other Big Stocks Moving Higher On Monday
Via Benzinga
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Revance Therapeutics, Inc.
Via Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Via The Motley Fool
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
Via InvestorPlace
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Via InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
Via InvestorPlace
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Via Benzinga
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.